Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

Phase 1/2 Completed 102 enrolled Millennium Pharmaceuticals, Inc.

Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with Docetaxel (Taxotere) to patients with androgen-independent prostate cancer, and also to see what effects (good and bad) it has on you and on your cancer.

Timeline

Start: 2002-12
Primary completion: 2004-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	—	—

Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

Summary

Timeline

Drugs

Indications